COVID-19: Molecular and Cellular Response
暂无分享,去创建一个
I. Adcock | E. Mortaz | H. Bayram | P. Tabarsi | H. Jamaati | M. Varahram | S. Alipoor
[1] T. White. The Trinity , 2022 .
[2] A. Raj,et al. Sex differences in COVID-19 case fatality: do we know enough? , 2020, The Lancet Global Health.
[3] K. Peter,et al. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities , 2020, Cardiovascular research.
[4] V. Galasso,et al. Gender differences in COVID-19 attitudes and behavior: Panel evidence from eight countries , 2020, Proceedings of the National Academy of Sciences.
[5] Arthur S Slutsky,et al. Human recombinant soluble ACE2 in severe COVID-19 , 2020, The Lancet Respiratory Medicine.
[6] A. Pradhan,et al. Sex differences in severity and mortality from COVID-19: are males more vulnerable? , 2020, Biology of sex differences.
[7] Vineet D. Menachery,et al. Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV , 2020, Journal of Virology.
[8] S. Farhadian,et al. Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.
[9] I. Adcock,et al. The Immune Response and Immunopathology of COVID-19 , 2020, Frontiers in Immunology.
[10] R. Cox,et al. Not just antibodies: B cells and T cells mediate immunity to COVID-19 , 2020, Nature Reviews Immunology.
[11] M. Endres,et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model , 2020, bioRxiv.
[12] L. Carter,et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 , 2020, medRxiv.
[13] N. Rezaei,et al. Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor? , 2020, The American Journal of the Medical Sciences.
[14] Martin Linster,et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.
[15] Maciej Banach,et al. Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper , 2020, Frontiers in Immunology.
[16] A. Sette,et al. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns , 2020, Nature Reviews Immunology.
[17] Ying Li,et al. Antibody responses against SARS‐CoV‐2 in COVID‐19 patients , 2020, Journal of medical virology.
[18] A. Velde,et al. Severe COVID-19: NLRP3 Inflammasome Dysregulated , 2020 .
[19] T. Swartz,et al. Targeting the NLRP3 Inflammasome in Severe COVID-19 , 2020, Frontiers in Immunology.
[20] Quanlong Jiang,et al. Individual variation of the SARS‐CoV‐2 receptor ACE2 gene expression and regulation , 2020, Aging cell.
[21] S. Atal,et al. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? , 2020, Pharmaceutical Medicine.
[22] G. Keser,et al. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment , 2020, Clinical Rheumatology.
[23] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[24] A. Shah. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19 , 2020, Frontiers in Immunology.
[25] L. Rodríguez-Mañas,et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study , 2020, The Lancet.
[26] H. Tang,et al. Severe COVID-19: A Review of Recent Progress With a Look Toward the Future , 2020, Frontiers in Public Health.
[27] G. Antonucci,et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease , 2020, Journal of Allergy and Clinical Immunology.
[28] Malik Peiris,et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures , 2020, The Lancet Respiratory Medicine.
[29] A. Zangrillo,et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.
[30] Fang Li,et al. Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.
[31] M. Merad,et al. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.
[32] D. Roden,et al. Genetic susceptibility for COVID-19–associated sudden cardiac death in African Americans , 2020, Heart Rhythm.
[33] Thomas Henry,et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions , 2020, Autoimmunity Reviews.
[34] S. Surani,et al. A Review of Neurological Complications of COVID-19 , 2020, Cureus.
[35] B. Williams,et al. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19 , 2020, The Lancet.
[36] F. Rodríguez de Fonseca,et al. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: A delayed pandemic?? , 2020, Neurología (English Edition).
[37] X. Tang,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[38] M. Tay,et al. The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.
[39] E. Swenson,et al. COVID-19 Lung Injury and High Altitude Pulmonary Edema: A False Equation with Dangerous Implications. , 2020, Annals of the American Thoracic Society.
[40] Fabian J Theis,et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.
[41] M. Diamond,et al. TMPRSS2 and TMPRSS4 mediate SARS-CoV-2 infection of human small intestinal enterocytes , 2020, bioRxiv.
[42] T. Liang,et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study , 2020, BMJ.
[43] Matthew D. Park,et al. Macrophages: a Trojan horse in COVID-19? , 2020, Nature Reviews Immunology.
[44] Nan Tang,et al. SARS-CoV-2 and viral sepsis: observations and hypotheses , 2020, The Lancet.
[45] F. R. de Fonseca,et al. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? , 2020, Neurologia.
[46] A. Topeli,et al. Critically ill COVID-19 patient , 2020, Turkish journal of medical sciences.
[47] C. Yancy,et al. COVID-19 and African Americans. , 2020, JAMA.
[48] Zhengrong Yang,et al. Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation , 2020, Scientific Reports.
[49] T. Lv,et al. Encephalitis as a clinical manifestation of COVID-19 , 2020, Brain, Behavior, and Immunity.
[50] L. Mao,et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.
[51] Jun Liu,et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[52] Harapan Harapan,et al. Coronavirus disease 2019 (COVID-19): A literature review , 2020, Journal of Infection and Public Health.
[53] Robert J. Mason,et al. Pathogenesis of COVID-19 from a cell biologic perspective , 2020, European Respiratory Journal.
[54] K. Hashimoto,et al. Nervous system involvement after infection with COVID-19 and other coronaviruses , 2020, Brain, Behavior, and Immunity.
[55] Zhiyong Ma,et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia , 2020, The Journal of infectious diseases.
[56] Hongyang Wang,et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing , 2020, Cell Discovery.
[57] Manish Bansal,et al. Cardiovascular disease and COVID-19 , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[58] K. Shi,et al. Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.
[59] Shibo Jiang,et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.
[60] E. Holmes,et al. The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.
[61] Usman Ali,et al. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms , 2020, ACS chemical neuroscience.
[62] Fabian J Theis,et al. SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways , 2020, Nature Medicine.
[63] Srinivas Murthy,et al. Care for Critically Ill Patients With COVID-19. , 2020, JAMA.
[64] S. Xiao,et al. Clinical outcomes of 402 patients with COVID‐2019 from a single center in Wuhan, China , 2020, medRxiv.
[65] Vineet D. Menachery,et al. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. , 2020, bioRxiv.
[66] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[67] Chang Hu,et al. Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, medRxiv.
[68] Xiaowei Li,et al. Molecular immune pathogenesis and diagnosis of COVID-19 , 2020, Journal of Pharmaceutical Analysis.
[69] Xiang Xie,et al. COVID-19 and the cardiovascular system , 2020, Nature Reviews Cardiology.
[70] Liang Peng,et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report , 2020, International Journal of Infectious Diseases.
[71] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[72] D. Gurwitz. Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics , 2020, Drug development research.
[73] Mario Plebani,et al. Laboratory abnormalities in patients with COVID-2019 infection , 2020, Clinical chemistry and laboratory medicine.
[74] H. G. Liu,et al. [Cause analysis and treatment strategies of "recurrence" with novel coronavirus pneumonia (covid-19) patients after discharge from hospital]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[75] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[76] T. Palaga,et al. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. , 2020, Asian Pacific journal of allergy and immunology.
[77] De-Min Han,et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality , 2020, Frontiers in Public Health.
[78] Taiwen Li,et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa , 2020, International Journal of Oral Science.
[79] M. Letko,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[80] Shengqing Wan,et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations , 2020, Cell Discovery.
[81] L. Mao,et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study , 2020, medRxiv.
[82] H. Shan,et al. Evidence for Gastrointestinal Infection of SARS-CoV-2 , 2020, Gastroenterology.
[83] Bo Diao,et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.
[84] Min Kang,et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.
[85] Jiyuan Zhang,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.
[86] Novel Coronavirus Pneumonia Emergency Response Epidemiol Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.
[87] B. Canard,et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade , 2020, Antiviral Research.
[88] E. Stoneman,et al. The Novel Coronavirus: A Bird's Eye View , 2020, The international journal of occupational and environmental medicine.
[89] Gengfu Xiao,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[90] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[91] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[92] Immune Cell , 2020, Definitions.
[93] E. Holmes,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.
[94] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[95] Ralph S. Baric,et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.
[96] Hongzhou Lu,et al. Drug treatment options for the 2019-new coronavirus (2019-nCoV). , 2020, Bioscience trends.
[97] W. Zuo,et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov , 2020, bioRxiv.
[98] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[99] Alain Le Coupanec,et al. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? , 2019, Viruses.
[100] N. Jouvenet,et al. Stimulation of Innate Immunity by Host and Viral RNAs. , 2019, Trends in immunology.
[101] R. Plemper,et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia , 2019, Science Translational Medicine.
[102] F. Delalande,et al. Zika virus enhances monocyte adhesion and transmigration favoring viral dissemination to neural cells , 2019, Nature Communications.
[103] David K. Meyerholz,et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. , 2019, The Journal of clinical investigation.
[104] D. Sauter,et al. Furin‐mediated protein processing in infectious diseases and cancer , 2019, Clinical & translational immunology.
[105] N. Badae,et al. Is the cardioprotective effect of the ACE2 activator diminazene aceturate more potent than the ACE inhibitor enalapril on acute myocardial infarction in rats? , 2019, Canadian journal of physiology and pharmacology.
[106] Takeshi Ichinohe,et al. Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome , 2019, Front. Microbiol..
[107] Simon A. Jones,et al. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer , 2018, Nature Reviews Immunology.
[108] Reza Taherkhani,et al. Modulation of the immune response by Middle East respiratory syndrome coronavirus , 2018, Journal of cellular physiology.
[109] K. Pyrć,et al. Early events during human coronavirus OC43 entry to the cell , 2018, Scientific Reports.
[110] P. Thomas,et al. New fronts emerge in the influenza cytokine storm , 2017, Seminars in Immunopathology.
[111] S. Perlman,et al. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.
[112] Yi Shi,et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains , 2017, Nature Communications.
[113] G. Gao,et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV , 2016, Antiviral Research.
[114] F. Weber,et al. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response , 2016, Advances in Virus Research.
[115] D. Libraty,et al. A Model to Explain How the Bacille Calmette Guérin (BCG) Vaccine Drives Interleukin-12 Production in Neonates , 2016, PloS one.
[116] A. Hajeer,et al. Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection , 2016, Annals of thoracic medicine.
[117] G. Gao,et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses , 2016, Trends in Microbiology.
[118] B. Rosenzweig,et al. The Effect of Oseltamivir on the Disease Progression of Lethal Influenza A Virus Infection: Plasma Cytokine and miRNA Responses in a Mouse Model , 2016, Disease markers.
[119] P. Daszak,et al. Isolation and Characterization of a Novel Bat Coronavirus Closely Related to the Direct Progenitor of Severe Acute Respiratory Syndrome Coronavirus , 2015, Journal of Virology.
[120] Ben Hu,et al. Bat origin of human coronaviruses , 2015, Virology Journal.
[121] T. Morio,et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan , 2015, Annals of the rheumatic diseases.
[122] Wenjie Tan,et al. Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets , 2015, Scientific Reports.
[123] Lisa E. Gralinski,et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.
[124] G. Burmester,et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial , 2015, Annals of the rheumatic diseases.
[125] I. Mori. Transolfactory neuroinvasion by viruses threatens the human brain. , 2015, Acta virologica.
[126] W. Liu,et al. Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection , 2015, Journal of Infection.
[127] S. Perlman,et al. Coronaviruses: An Overview of Their Replication and Pathogenesis , 2015, Methods in molecular biology.
[128] G. Whittaker,et al. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein , 2014, Proceedings of the National Academy of Sciences.
[129] P. Ades. A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. , 2014, Coronary artery disease.
[130] F. Luft. ACE in the hole , 2014, Journal of Molecular Medicine.
[131] G. Lynch,et al. Influence of HLA gene polymorphisms on susceptibility and outcome post infection with the SARS-CoV virus , 2014, Virologica Sinica.
[132] Yang Yang,et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists , 2013, Protein & Cell.
[133] J. Epstein,et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor , 2013, Nature.
[134] C. Lang,et al. Renin–Angiotensin–Aldosterone System Inhibitors in Heart Failure , 2013, Clinical pharmacology and therapeutics.
[135] F. Weber,et al. Middle East Respiratory Syndrome Coronavirus Accessory Protein 4a Is a Type I Interferon Antagonist , 2013, Journal of Virology.
[136] Linqi Zhang,et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 , 2013, Cell Research.
[137] Yoko Ito,et al. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. , 2013, American journal of respiratory cell and molecular biology.
[138] G. Whittaker,et al. Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein , 2012, Viruses.
[139] Yen-Ju Chen,et al. Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. , 2011, Viral immunology.
[140] Yoko Ito,et al. Innate immune response to influenza A virus in differentiated human alveolar type II cells. , 2011, American journal of respiratory cell and molecular biology.
[141] E John Wherry,et al. T cell exhaustion , 2011 .
[142] Josef M. Penninger,et al. Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters , 2010, Pharmacology & Therapeutics.
[143] G. Whittaker,et al. Modifications to the Hemagglutinin Cleavage Site Control the Virulence of a Neurotropic H1N1 Influenza Virus , 2010, Journal of Virology.
[144] F. Plummer,et al. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology , 2010, mAbs.
[145] K. Mayer,et al. Targeting Trojan Horse leukocytes for HIV prevention , 2010, AIDS.
[146] S. Perlman,et al. Coronaviruses post-SARS: update on replication and pathogenesis , 2009, Nature Reviews Microbiology.
[147] B. Berkhout,et al. Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2 , 2008, The Journal of general virology.
[148] A. McMichael,et al. T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.
[149] G. Bakris,et al. The pathogenesis of diabetic nephropathy , 2008, Nature Clinical Practice Endocrinology &Metabolism.
[150] David K. Meyerholz,et al. Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2 , 2008, Journal of Virology.
[151] S. Crotty,et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade , 2006, The Journal of Experimental Medicine.
[152] L. Teyton,et al. Interleukin-10 determines viral clearance or persistence in vivo , 2006, Nature Medicine.
[153] S. Perlman,et al. Immunopathogenesis of coronavirus infections: implications for SARS , 2005, Nature Reviews Immunology.
[154] S. Diamond,et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[155] Bo Zhang,et al. Multiple organ infection and the pathogenesis of SARS , 2005, The Journal of experimental medicine.
[156] Ben Berkhout,et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[157] K. Kain,et al. Fatal Severe Acute Respiratory Syndrome Is Associated with Multiorgan Involvement by Coronavirus , 2005, The Journal of infectious diseases.
[158] R. D. de Groot,et al. Natural History of a Recurrent Feline Coronavirus Infection and the Role of Cellular Immunity in Survival and Disease , 2005, Journal of Virology.
[159] D. Furst. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. , 2004, Clinical therapeutics.
[160] Larissa B. Thackray,et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[161] C. Perry. Clinical Features , 2004, Bristol medico-chirurgical journal.
[162] B. Bosch,et al. The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex , 2003, Journal of Virology.
[163] A. Xu,et al. Profile of specific antibodies to the SARS-associated coronavirus. , 2003, The New England journal of medicine.
[164] Obi L. Griffith,et al. The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.
[165] L. Poon,et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .
[166] S. Aggarwal,et al. Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. , 1999, Journal of immunology.
[167] S. Aggarwal,et al. Increased TNF-α-Induced Apoptosis in Lymphocytes from Aged Humans: Changes in TNF-α Receptor Expression and Activation of Caspases , 1999, The Journal of Immunology.
[168] R. Webster,et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus , 1998, The Lancet.
[169] S. Perlman,et al. Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain , 1990, The Journal of experimental medicine.
[170] M. Pensaert,et al. Immunofluorescence studies on the pathogenesis of hemagglutinating encephalomyelitis virus infection in pigs after oronasal inoculation. , 1980, American journal of veterinary research.
[171] M. Moosavi,et al. Cytokine-targeted therapy in severely ill COVID-19 patients: Options and cautions , 2020 .
[172] M. Rithanya,et al. Molecular Immune Pathogenesis and Diagnosis of COVID-19 - A Review , 2020 .
[173] China Cdc Weekly. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 , 2020, China CDC weekly.
[174] S. Sekaran,et al. Disruption of the blood brain barrier is vital property of neurotropic viral infection of the central nervous system. , 2018, Acta virologica.
[175] P. Song,et al. CLINICAL OUTCOMES? , 2014 .
[176] Hiroshi Kido,et al. Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure. , 2012, Biochimica et biophysica acta.
[177] A. Davies,et al. Immune Responses , 1971, Nature.